Abstract

Liposarcoma (LPS) is among the most common soft-tissue sarcomas, yet it encompasses a heterogeneous group of histologic subtypes with distinctly different prognoses. This narrative review synthesises survival outcomes and prognostic factors by subtype—including well-differentiated (WDLPS), myxoid/round-cell (MLPS/RCLS), pleomorphic (PLPS), and dedifferentiated LPS (DDLPS). Data is drawn from major population-level registries (SEER, ICES) and institutional cohorts. WDLPS and MLPS generally demonstrate favourable 5-year survival (>75–90%), while PLPS and DDLPS are associated with significantly worse outcomes (5-year overall survival ~50%). Important prognostic variables include tumour grade, size, location, margin status, patient age, sex, and treatment modalities such as surgery, radiation, and chemotherapy. These findings underscore that LPS subtypes cannot be treated as a single entity. Subtype-specific treatment and surveillance strategies are warranted to optimise patient outcomes and minimise morbidity.

Introduction

Liposarcoma is a malignant adipocytic neoplasm accounting for roughly 20% of adult soft-tissue sarcomas, with an incidence of 2.5 cases per million per year globally.^1,2 Its diagnosis spans several histologic types, WDLPS, MLPS (including round-cell variant), PLPS, and DDLPS, each demonstrating distinct biological behaviour and survival profiles.^3,4 Despite their relative rarity, recent large-scale registry data have enabled more granular comparisons of survival metrics across subtypes, highlighting the need for tailored management paradigms.^3,4,5 This review consolidates survival statistics, discusses demographic and treatment-related prognostic factors, and explores opportunities for more individualised care.

Epidemiological overview & data sources

Population-level analyses, notably from the SEER (Surveillance, Epidemiology, and End Results) program and Canada’s ICES (Institute for Clinical Evaluative Sciences), form the backbone of our current understanding of LPS subtype outcomes.^3,5 Comparisons between these datasets confirm consistent trends in subtype demographics and prognosis, despite 

variations in sampling. Meanwhile, institution-based series, such as the multicenter European cohort spanning 1985–2015, provide deeper clinical context and subtype-specific survival estimates.⁶

Well-differentiated liposarcoma (WDLPS)

WDLPS, also known as atypical lipomatous tumours when located in the limbs, represents the most common subtype, comprising 40–45% of cases.⁵ Characterised by low metastatic potential, WDLPS frequently recurs locally, particularly after incomplete excision, yet demonstrates excellent long-term survival.^3,5 In the SEER dataset, the 5-year survival rate for WDLPS reaches approximately 82%, with a 10-year survival near 67%.⁵ ICES data show even more favourable outcomes (5-year 90%, 10-year 81%).⁵ Median survival in the ICES cohort exceeds 40 years.⁵ Studies like Arvinius et al. further highlight low metastatic risk but underscore a roughly 50% local recurrence rate over long-term follow-up.⁶ Despite frequent local recurrences, WDLPS patients seldom experience disease-related mortality, underscoring the importance of margin-negative resection and surveillance. Surveillance intensity may be reduced compared with other subtypes, with some advocating for a more conservative approach to balance quality of life and resource utilisation.⁶

Myxoid/round-cell liposarcoma (MLPS/RCLS)

Representing around 30% of LPS cases, MLPS is typically low to intermediate grade, whereas the round-cell variant is considered high grade.⁷ In survival analyses, MLPS patients show favourable 5-year overall survival between 76–88% in SEER and ICES data.^7,8 Median survival often exceeds 40 years 7. High-grade round-cell variants fare worse, with higher metastatic rates and less chemotherapy responsiveness, resulting in reduced survival compared to low-grade MLPS 8,9. Even so, MLPS outcomes remain comparatively strong versus other subtypes. It typically presents in younger individuals (mean age ~50 years vs. ~62 for WDLPS).⁹ Factors like tumour size ≥10 cm, male sex, older age, and presence of round-cell components independently predict poorer prognosis.^8-10 Management often includes surgery with radiotherapy, and MLPS demonstrates sensitivity to chemotherapy agents such as trabectedin or anthracyclines when high-risk features are present.^9,10

Dedifferentiated liposarcoma (DDLPS)

DDLPS accounts for approximately 10–20% of cases and may emerge de novo or from pre-existing WDLPS.¹¹ It is characterised histologically by areas of higher-grade sarcoma juxtaposed with adipocytic differentiation and is associated with aggressive clinical behaviour. In the SEER dataset, DDLPS exhibits markedly poor outcomes, with 5-year overall survival (~49%) and 10-year survival (~32%).¹¹ ICES shows higher rates (~75% at 5 years, ~67% at 10 

years), suggesting potential regional or time-based variation.¹¹ Retrospective European studies consistently identify DDLPS as the subtype with the lowest median survival compared to WDLPS and MLPS.¹² Significant negative prognostic factors include increasing age, high tumour grade, larger primary tumour, and non-extremity location.^11,12

Pleomorphic liposarcoma (PLPS)

PLPS is the rarest and most aggressive LPS subtype, constituting 5–10% of cases.¹³ It lacks a consistent molecular signature, has high-grade histology, and behaves aggressively.¹⁴ SEER and ICES data likewise reflect poor survival, with 5-year overall survival rates around 51% and 47% respectively, and 10-year survival dipping below 35%.¹³ Institutional data further confirms a median survival of below 50% and a metastasis rate exceeding 30%.¹⁴ Local recurrence and metastatic spread are common, with male sex and non-extremity location correlating with the worst outcomes.^13,14

Comparative survival outcomes: summary

A recent European multicenter study of 456 extremity LPS patients showed significantly varied outcomes: WDLPS had a 5-year overall survival of 92%, MLPS 79.7%, DDLPS 54.4%, and PLPS 47.6% (p < 0.001).¹⁴ Distant metastasis-free survival and local recurrence-free survival also followed subtype-dependent patterns: 97.3% and 77% in WDLPS, 74% and 84.5% in MLPS, 86.3% and 62.4% in DDLPS, and 46.9% and 71.4% in PLPS, respectively.¹⁴

Prognostic factors across subtypes

 Risk stratification relies on evaluating multiple factors:

• Histologic subtype: the most critical determinant of survival¹⁵
• Tumour grade and size: High-grade tumours and larger lesions (>5–10 cm) predict worse outcomes¹⁵
• Surgical margin status: Negative resection margins confer a significant survival advantage¹⁵
• Location: Retroperitoneal and trunk LPS have a worse prognosis than extremity tumors¹⁵
• Age and sex: Older age (>50 years) and male sex correlate with higher mortality¹⁵
• Metastases: Presence at diagnosis is universally associated with poor survival¹⁵

Treatment modalities and survival impact

Wide surgical excision with negative margins remains the cornerstone treatment across subtypes, offering the best chance of long-term survival.¹⁶ Data from the SEER and BMC Cancer cohort suggest a protective effect of radiotherapy, except in WDLPS, likely reflecting its role in controlling microscopic disease.¹⁶ Conversely, chemotherapy appears beneficial in WDLPS and MLPS but not in PLPS or DDLPS, where robust trials are lacking.¹⁶ Emerging systemic agents such as trabectedin show promise in MLPS, particularly in advanced disease, though longer-term survival impact remains to be fully defined.¹⁶

Clinical implications & surveillance strategies

The distinct survival trajectories underscore the importance of subtype-specific care. While WDLPS may require less aggressive surveillance, subtypes such as PLPS and DDLPS mandate intensive follow-up and consideration of multi-modality treatment. Surveillance frequency, imaging modality, and thresholds for systemic therapy should be informed by histologic subtype, tumour grade, and patient factors. Shared decision-making—factoring in quality-of-life considerations—is equally vital, especially in advanced cases where the risk-benefit ratio of adjuvant therapies may vary.

Limitations & research gaps

Retrospective registry data are limited by missing variables (e.g., margin status, adjuvant therapy details) and potential coding bias.¹⁷ Heterogeneity in institutional treatment protocols further complicates outcome assessment.¹⁷ Prospective, subtype-specific clinical trials are needed to optimise therapeutic sequencing and validate emerging agents across LPS subtypes.

Conclusions

Liposarcoma comprises a spectrum of histologic subtypes with widely divergent survival outcomes. Well-differentiated and myxoid variants generally have favourable survival, whereas pleomorphic and dedifferentiated types carry poor prognoses. Subtype, grade, tumour size, margins, location, patient demographics, and metastasis status all independently influence survival. Subtype-specific treatment regimens and surveillance strategies should be viewed as essential components of contemporary LPS management.